--- title: "Processa Pharmaceuticals (PCSA) news: reverse split and offering" url: "https://aibio.space/companies/processa-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PCSA reverse split and offering news: Processa Pharmaceuticals gets second 180-day Nasdaq period to fix bid price. Processa Pharmaceuticals, Inc." --- PCSA Processa Pharmaceuticals, Inc. NASDAQ · United States # Processa Pharmaceuticals (PCSA) news PCSA reverse split and offering news Company Updates · 2026-10-29 ## [Processa clears VT-7208 CSU IND and names a new executive chair](https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/) Processa said the FDA cleared an IND for a study of VT-7208 in chronic spontaneous urticaria, expected to enroll approximately 120 adults, and that its cash should fund operations into the second half of 2029. ## Latest Processa Pharmaceuticals news 1. 2026-07-29 Mergers [Processa acquires Vidya Therapeutics with $200 million placement](https://aibio.space/news/processa-acquires-vidya-therapeutics-200-million-placement/) Processa said it acquired Vidya Therapeutics, whose lead asset is the BTK inhibitor VT-7208, alongside a concurrent private placement of approximately $200 million. 2. 2025-08-08 Listings [Processa Pharmaceuticals gets second 180-day Nasdaq period to fix bid price](https://aibio.space/news/processa-pharmaceuticals-gets-second-180-day-nasdaq-period-fix-bid/) Nasdaq has given Processa until February 2, 2026 to bring its share price back to at least $1, a second 180-day period. The company says it will consider a reverse stock split, and the filing gives no recent share price to show how far it is from the threshold. 3. 2025-08-07 Financings [Processa Pharmaceuticals sells 5,467,181 shares in $1.3 million private placement at $0.23](https://aibio.space/news/processa-pharmaceuticals-sells-5-467-181-shares-1-3-million-private/) Processa says the private placement closed August 6, 2025, with LifeSci Capital LLC as exclusive placement agent. The company also says it is evaluating corporate cryptocurrency treasury strategies. 4. 2025-07-25 Financings [Processa Pharmaceuticals registers up to $5,239,073 in at-the-market stock sales](https://aibio.space/news/processa-pharmaceuticals-registers-up-5-239-073-market-stock-sales/) Processa filed a new prospectus supplement that lets it sell up to $5,239,073 of stock through its at-the-market program with A.G.P./Alliance Global Partners. Its shares closed at $0.2497 on July 22, 2025, down from $0.40 on June 11, 2025, the date its public float was measured. ## Processa Pharmaceuticals at a glance - **Ticker**: PCSA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $196,325 ### Related companies - [Petros Pharmaceuticals](https://aibio.space/companies/petros-pharmaceuticals/) OTC: PTPI - [Hepion Pharmaceuticals](https://aibio.space/companies/hepion-pharmaceuticals/) OTC: HEPA - [Fortress Biotech](https://aibio.space/companies/fortress-biotech/) NASDAQ: FBIO - [Atossa Therapeutics](https://aibio.space/companies/atossa-therapeutics/) NASDAQ: ATOS - [Relmada Therapeutics](https://aibio.space/companies/relmada-therapeutics/) NASDAQ: RLMD - [Kairos Pharma](https://aibio.space/companies/kairos-pharma/) AMEX: KAPA - [Atea Pharmaceuticals](https://aibio.space/companies/atea-pharmaceuticals/) NASDAQ: AVIR - [Evelo Biosciences](https://aibio.space/companies/evelo-biosciences/) OTC: EVLO ### Also on NASDAQ - [ALX Oncology Holdings](https://aibio.space/companies/alx-oncology/) ALXO - [SeaStar Medical Holding](https://aibio.space/companies/seastar-medical/) ICU - [IRulya Therapeutics](https://aibio.space/companies/irulya-therapeutics-qncx/) QNCX - [TriSalus Life Sciences](https://aibio.space/companies/trisalus-life-sciences/) TLSI - [AVITA Medical](https://aibio.space/companies/avita-medical/) RCEL - [Decoy Therapeutics](https://aibio.space/companies/decoy-therapeutics/) DCOY ## Processa Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$13.6 million](https://www.sec.gov/Archives/edgar/data/1533743/000149315226011204/) | [-$11.9 million](https://www.sec.gov/Archives/edgar/data/1533743/000149315226011204/) | | Cash from operations | [-$11.4 million](https://www.sec.gov/Archives/edgar/data/1533743/000149315226011204/) | [-$11.2 million](https://www.sec.gov/Archives/edgar/data/1533743/000149315226011204/) | | Cash and equivalents | [$5.5 million](https://www.sec.gov/Archives/edgar/data/1533743/000149315226038334/) | [$1.2 million](https://www.sec.gov/Archives/edgar/data/1533743/000149315226011204/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $196,325. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Processa Pharmaceuticals Did Processa Pharmaceuticals do a reverse stock split? Our latest story on this, dated Aug 8, 2025: "Processa Pharmaceuticals gets second 180-day Nasdaq period to fix bid price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/processa-pharmaceuticals-gets-second-180-day-nasdaq-period-fix-bid/). Has Processa Pharmaceuticals raised money recently? Our latest story on this, dated Jul 29, 2026: "Processa acquires Vidya Therapeutics with $200 million placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/processa-acquires-vidya-therapeutics-200-million-placement/). What is the ticker symbol of Processa Pharmaceuticals? Processa Pharmaceuticals, Inc. trades under the ticker PCSA on NASDAQ. Where is Processa Pharmaceuticals listed? Processa Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Processa Pharmaceuticals? The SEC Central Index Key (CIK) for Processa Pharmaceuticals, Inc. is 1533743. Its filings are on SEC EDGAR. How many shares does Processa Pharmaceuticals have outstanding? 2,793,386 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Processa Pharmaceuticals listed under? Our directory records Processa Pharmaceuticals, Inc. under United States. What does Processa Pharmaceuticals do? Our directory classifies Processa Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Processa Pharmaceuticals? The ISIN recorded for Processa Pharmaceuticals, Inc. is US74275C4033. Does aibio.space cover Processa Pharmaceuticals? aibio.space lists Processa Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Processa Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. Is Processa Pharmaceuticals profitable? Processa Pharmaceuticals, Inc. reported a net loss of $13.6 million for the fiscal year ended Dec 31, 2025, and used $11.4 million of cash in operations, per its annual report to the SEC. How much cash does Processa Pharmaceuticals have? $196,325 in cash at Jun 30, 2026, per its 10-Q. What is the latest Processa Pharmaceuticals (PCSA) stock news? Our latest story on Processa Pharmaceuticals, dated Oct 29, 2026: "Processa clears VT-7208 CSU IND and names a new executive chair". Processa said the FDA cleared an IND for a study of VT-7208 in chronic spontaneous urticaria, expected to enroll approximately 120 adults, and that its cash should fund operations into the second half of 2029. [Source](https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/). How long will Processa Pharmaceuticals's cash last? From our story of Oct 29, 2026: Processa said the FDA cleared an IND for a study of VT-7208 in chronic spontaneous urticaria, expected to enroll approximately 120 adults, and that its cash should fund operations into the second half of 2029. [Source](https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/). ## Investor discussion: Processa Pharmaceuticals Members talk about Processa Pharmaceuticals (PCSA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Processa Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-22 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1533743/000114036126040520/ny20083166x3_def14a.htm) 2. 2026-10-09 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1533743/000114036126039267/ny20083166x1_pre14a.htm) 3. 2026-07-29 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,1.02,2.01,3.02,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315226035099/ex99-1.htm) 4. 2026-03-18 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315226011204/form10-k.htm) 5. 2026-02-19 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315226007469/form8-k.htm) 6. 2026-01-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315226000733/form8-k.htm) 7. 2025-12-15 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315225027680/form8-k.htm) 8. 2025-09-12 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315225013108/form8-k.htm) 9. 2025-08-13 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315225011883/formdef14a.htm) 10. 2025-08-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315225011775/form8-k.htm) 11. 2025-08-07 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315225011680/ex99-1.htm) 12. 2025-07-31 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315225011519/formpre14a.htm) 13. 2025-07-25 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315225011418/form424b5.htm) 14. 2025-06-13 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1533743/000164117225014967/forms-1.htm) 15. 2025-05-12 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1533743/000164117225009671/formdef14a.htm) 16. 2025-05-01 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1533743/000164117225008097/formpre14a.htm) 17. 2025-03-20 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1533743/000164117225000070/form10-k.htm) 18. 2025-02-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315225005633/form8-k.htm) 19. 2024-12-20 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315224051075/forms-1.htm) 20. 2024-11-06 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1533743/000149315224043821/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PCSA on TradingView](https://www.tradingview.com/symbols/NASDAQ-PCSA/). ## SEC filings and registration - **SEC name**: Processa Pharmaceuticals, Inc. - **CIK**: 1533743 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PCSA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 601 21ST STREET, SUITE 300, VERO BEACH, FL, 32960 - **Phone**: 443-776-3133 - **Shares outstanding**: 2,793,386 as of 2026-08-07 (10-Q filed 2026-08-14) - **Former names**: Heatwurx, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1533743/000114036126040520/ny20083166x3_def14a.htm) filed 2026-10-22 - [S-3](https://www.sec.gov/Archives/edgar/data/1533743/000114036126039266/ny20083513x1_s3.htm) filed 2026-10-09 - [10-Q](https://www.sec.gov/Archives/edgar/data/1533743/000149315226038334/form10-q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1533743/000149315226036032/form8-k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1533743/000149315226035099/form8-k.htm) filed 2026-07-29 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1533743/000149315226029326/formdef14a.htm) filed 2026-06-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1533743/000149315226021721/form10-q.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1533743/000149315226020728/form8-k.htm) filed 2026-04-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001533743), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Processa Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PCSA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Processa Pharmaceuticals, Inc. - **Ticker**: PCSA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US74275C4033 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PCSA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/processa-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Processa Pharmaceuticals (PCSA) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/processa-pharmaceuticals/